Treating childhood acute lymphoblastic leukemia without cranial irradiation.
By Ching-Hon Pui, Dario Campana, Deqing Pei, W. Bowman, J. Sandlund, S. Kaste, Raul C. Ribeiro, J. Rubnitz, S. Raimondi, M. Onciu and 14 more. New England Journal of Medicine, 2009
1,165 citations recorded by the source corpus.
Subfields: Genetics, Hematology, Public Health, Environmental and Occupational Health
View Paper: https://www.semanticscholar.org/paper/cacf2f7f37cfa429b1bb941db105c966c7a14b7e
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
In Hematology
In Public Health, Environmental and Occupational Health
Citations in the corpus
- Cancer treatment and survivorship statistics, 2012 (2012, background): “More than 95% of children with ALL attain remission.(36,37) Pediatric patients with ALL (aged birth to 17 years) who survive 5 years or longer have a 5-fold increased risk of a second primary malignancy compared with the general population, while adult-onset disease confers no excess risk.”
- Biology, risk stratification, and therapy of pediatric acute leukemias: an update. (2011, background): “3) [TCF3-HLF], remission induction failure, and the presence of MRD more than 1% at the end of remission induction are also associated with dismal outcome and collectively occur in approximately 5% of children with ALL.31 Although allogeneic transplantation is frequently used to treat these patients”
- Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. (2013, background): “…these notions, high expression levels of CD39 and CD73 correlate with poor disease outcome in patients affected by chronic lymphocytic leukemia (Pulte et al., 2011), colorectal carcinoma (Wu et al., 2012), and estrogen receptor-negative, progesterone receptor-negative, and HER2-negative…”
- Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia (2012, methodology): “Jude Children’s Research Hospital Total XV (Pui et al., 2009) and Total XVI protocols (http://ClinicalTrials.”